Epigenetics of pituitary tumours: An update

Current Opinion in Endocrinology, Diabetes and Obesity

Volumn 21, Issue 4, 2014, Pages 299-305

  Farrell, William E ^a  

^a KEELE UNIVERSITY   (United Kingdom)

Author keywords

chromatin; CpG island; epidrugs; epigenetic; histones; methylation; miRNA; pituitary adenoma

Indexed keywords

BONE MORPHOGENETIC PROTEIN 4; DINUCLEOTIDE; GROWTH HORMONE; HISTONE; MICRORNA; RETINOIC ACID; SOMATOSTATIN RECEPTOR;

BREAST IMPLANT; CELL PROLIFERATION; CHROMATIN; CPG ISLAND; EPIGENETICS; GENE SILENCING; HORMONE SYNTHESIS; HUMAN; HYPOPHYSIS ADENOMA; HYPOPHYSIS CELL; HYPOPHYSIS TUMOR; IN VITRO STUDY; IN VIVO STUDY; KNOWLEDGE; METHYLATION; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; REPRESSOR GENE; REVIEW; ADENOMA; DNA METHYLATION; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENE TARGETING; GENETIC EPIGENESIS; GENETICS; METABOLISM; PITUITARY NEOPLASMS; PROCEDURES;

ADENOMA; BONE MORPHOGENETIC PROTEIN 4; CPG ISLANDS; DNA METHYLATION; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; GENE TARGETING; HISTONES; HUMANS; PITUITARY NEOPLASMS;

EID: 84903787838     PISSN: 1752296X     EISSN: 17522978     Source Type: Journal    
DOI: 10.1097/MED.0000000000000078     Document Type: Review

References (47)

1. VanDeva S, Jaffrain-Rea ML, Daly AF, et al. The genetics of pituitary aDenomas. Best Pract Res Clin Endocrinol Metab 2010; 24:461-476.
2. Du dley KJ, Revill K, Clayton RN, Farrell WE. Pituitary tumours: all silent on the epigenetics front. J Mol Endocrinol 2009; 42:461-468.
3. Melmed S. Pathogenesis of pituitary tumors. Nat Rev Endocrinol 2011; 7:257-266.
4. You JS, Jones PA. Cancer genetics and epigenetics: two siDes of the same coin? Cancer Cell 2012; 22:9-20.
5. Yacqub-Usman K, Ric hardson A, Duong CV, et al. The pituitary tumour epigenome: aberrations and prospects for targeted therapy. Nat Rev Endocrinol 2012; 8:486-494.
6. Zhou Y, Zhang X, Klibanski A. Genetic and epigenetic mutations of tumor suppressive genes in sporadic pituitary aDenoma. Mol Cell Endocrinol 2013; 386:16-33.
7. Pease M, Ling C, Mack WJ, et al. The role of epigenetic modification in tumorigenesi s and progression of pituitary aDenomas: a systematic review of the literature. PloS One 2013; 8:e82619.
8. Emes RD, Farrell WE. Make way for the ' next generation' : application and prospects for genome-wiDe, epigenome-specific technologies in endocrine research. J Mol Endocrinol 2012; 49:R19-R27.
9. GaDelha MR, Trivellin G, HernanDez Ramirez LC, Korbonits M. Genetics of pituitary aDenomas. Front Horm Res 2013; 41:111-140.
10. Asa SL, Ezzat S. Genomic approaches to problems in pituitary neoplasia. Endocrine Pathol 2013. [Epub ahead of print]
11. Sharma S, Kel ly TK, Jones PA. Epigenetics in cancer. Carcinogenesis 2010; 31:27-36.
12. Heyn H, Esteller M. DNA methylation profiling in the clinic: applications and challenges. Nat Rev Genet 2012; 13:679-692.
13. Rostad S. Pituitary aDenoma pathogenesis: an update. Curr Opin Endocrinol Diabet Obes 2012; 19:322-327.
14. Zhang X, Sun H, Danila DC, et al. Loss of expression of GADD45 gamma, a growth inhibitory gene, in human pituitary aDenomas: implications for tumorigenesis. J Clin Endocrinol Metab 2002; 87:1262-126 7. (Pubitemid 36121097)
15. Bahar A, Simpson DJ, Cutty SJ, et al. Isolation and characterization of a novel pituitary tumor apoptosis gene. Mol Endocrinol 2004; 18:1827-1839. (Pubitemid 38859588)
16. Shi X, Tao B, He H, et al. MicroRNAs-based network: a novel therapeutic agent in pituitary aDenoma. Med Hypotheses 2012; 78:380-384.
17. GaDelha MR,Kasuki L.Denes J,et al,MicroRNAs: Suggested role in pituitary aDenoma pathogenesis,J Endocrinol Invest,2013,36, 889-895.
18. Duong CV, Emes RD, Wessely F, et al. Quantitative, genome-wiDe analysis of the DNA methylome in sporadic pi tuitary aDenomas. Endocr Relat Cancer 2012; 19:805-816. First genome-wiDe investigation of the pituitary, aDenoma-associated epigenome.
19. Kelly TK, De Carvalho DD, Jones PA. Epigenetic modifications as therapeutic targets. Nat Biotechnol 2010; 28:1069-1078.
20. Yang X, Lay F, Han H, Jones PA. Targeting DNA methylation for epigenetic therapy. Trends Pharmacol Sci 2010; 31:536-546.
21. Yacqub-Usman K, Duong CV, Clayton RN, Farrell WE. Preincubation of pituitary tumor cells with the epidrugszebularine and trichostatinA are permissive for retinoic acid-augmented expression of the B MP-4 and D2R genes. Endocrinology 2013; 154:1711-1721.
22. Walton TJ, Li G, Seth R, et al. DNA Demethylation and histone Deacetylation inhibition co-operate to re-express estrogen receptor beta and induce apoptosis in prostate cancer cell-lines. The Prostate 2008; 68:210-222. (Pubitemid 351186233)
23. Gore SD, Hermes-DeSantis ER. Future directions in myelodysplastic syndrome: newer agents and the role of combination approaches. Cancer Control 2008; 15 (Suppl):40-49.
24. Bahar A, Bicknell JE, Simpson DJ, et al. Loss of expression of the growth inhibitory gene GADD45gamma, in human pituitary aDenomas, is asso ciated with CpG island methylation. Oncogene 2004; 23:936-944. (Pubitemid 38250939)
25. Zhao J, Dahle D, Zhou Y, et al. Hypermethylation of the promoter region is associated with the loss of MEG3 gene expression in h uman pituitary tumors. J Clin Endocrinol Metab 2005; 90:2179-2186. (Pubitemid 40586259)
26. Kim YH, Lee HC, Kim SY, et al. Epigenomic analysis of aberrantly methylated genes in colorectal cancer iDentifies genes comm only affected by epigenetic alterations. Ann Surg Oncol 2011; 18:2338-2347.
27. Wilop S, FernanDez AF, Jost E, et al. Array-based DNA methylation profiling in acute myeloid leukaemia. Brit J Haematol 2011; 155:65-72.
28. Zeller C, Dai W, Steele N L, et al. Candidate DNA methylation drivers of acquired cisplatin resistance in ovarian cancer iDentified by methylome and expression profiling. Oncogene 2012; 31:4567-4576.
29. Duong CV, Yacqub-Usm an K, Emes RD, et al. The EFEMP1 gene: a frequent target for epigenetic silencing in multiple human pituitary aDenoma subtypes. Neuroendocrinology 2013; 98:200-211.
30. Paez-Pereda M, Giacomini D, Refojo D, et al. Involvement of bone morphogenetic protein 4 (BMP-4) in pituitary prolactinoma pathogenesis through a Smad/estrogen receptor crosstalk. Proc Natl Acad Sci USA 2003; 100:1034-1039. (Pubitemid 36183950)
31. . Giacomini D, Paez-Pereda M, Theodoropoulou M, et al. Bone morphogenetic protein-4 inhibits corticotrophtumor cells: involvement in the retinoic acid inhibitory action. Endocrinology 2006; 147:247-256. (Pubitemid 43004278)
32. Giacomini D, Paez-Pereda M, Theodoropoulou M, et al. Bone morphogenetic protein-4 control of pituitary pathophysiology. Front Hormone Res 2006; 35:22-31. (Pubitemid 44024239)
33. Yacqub-Usman K, D uong CV, Clayton RN, Farrell WE. Epigenomic silencing of the BMP-4 gene in pituitary aDenomas: a potential target for epidruginduced re-expression. Endocrinology 2012.
34. Paez-Pereda M, Kovalovsky D, Hopfner U, et al. Retinoic acid prevents experimental Cushing syndrome. J Clin Invest 2001; 108:1123-1131. (Pubitemid 32995370)
35. Al-Azzawi H, Yacqub-Usman K, Richardson A, et al. Reversal of endogenous dopamine receptor silencing in pituitary cells augments receptor-mediated apoptosis. Endocrinology 2011; 152:364-373.
36. Ben-Shlomo A, Pichurin O, Khalafi R, et al. Constitutive somatostatin receptor subtype 2 activity attenuates GH synthesis. Endocrinology 2013; 154:2399-2409.
37. Veenstra MJ, De HerDer WW, FeelDers RA, Hofland LJ. Targeting the somatostatin receptor in pituitary and neuroen docrine tumors. Expert Opin Ther Targets 2013; 17:1329-1343.
38. Zamore PD, Haley B. Ribo-gnome: the big world of small RNAs. Science 2005; 309:1519-1524. (Pubitemid 41266468)
39. Huntzinger E,Izaurral De E,Gene silencing by microRNAs:contributions of translational repression and mRNA Decay,Nat Rev Genet,2011,12,99-110.
40. Bottoni A, Zatelli MC, Ferracin M, et a l. IDentification of differentially expressed microRNAs by microarray: a possible role for microRNA genes in pituitary aDenomas. J Cell Physiol 2007; 210:370-377. (Pubitemid 44956882)
41. Mao ZG, He DS, Zhou J, et al. Differential expression of microRNAs in GHsecreting pituitary aDenomas. Diagnost Pathol 2010; 5:79.
42. Butz H, Liko I, Czirjak S, e t al. MicroRNA profile indicates downregulation of the TGFbeta pathway in sporadic nonfunctioning pituitary aDenomas. Pituitary 2011; 14:112-124.
43. Jiang X, Zhang X. The molecular pathogenesis of pituitary aDenomas: an update. Endocrinol Metab 2013; 28:245-254.
44. Sivapragasam M, Rotondo F, Lloyd RV, et al. MicroRNAs in the human pituitary. Endocrine Pathol 2011; 22:134-143.
45. Palmieri D, D'Angelo D, Valentino T, et al. Downregulation of HMGA-targeting microRNAs has a critical role in human pituitary tumorigenesis. Oncogene 2012; 31:3857-3865.
46. D'Angelo D, Palmieri D, Mussnich P, et al. Altered microRNA expression profile in human pituitary GH aDenomas: down-regulation of miRNA targeting HMGA1, HMGA2, and E2F1. J Clin Endocrinol Metab 2012; 97:E1128-E1138.
47. Palumbo T, Faucz FR, Azevedo M, et al. Functional screen analysis reveals miR-26b and miR-128 as central regulators of pituitary somatomammotrophic tumor growth through activation of the PTEN-AK T pathway. Oncogene 2013; 32:1651-1659.